RNLXD (Renalytix) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


RNLXD Renalytix PLC RNLXD
46 GF Score
Price $4.11
GF Value $10.82
! 3 Warning Signs
View Full Analysis

What is Renalytix Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Renalytix's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

RNLXD vs VEEV, BTSG, TEM: Margin of Safety % (DCF Earnings Based) Comparison

For the Health Information Services subindustry, Renalytix's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renalytix Margin of Safety % (DCF Earnings Based) vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Renalytix's Margin of Safety % (DCF Earnings Based) falls into.


RNLXD
46GF Score
Renalytix PLC RNLXD
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Renalytix (RNLXD) Overvalued in 2026?

Based on GuruFocus' analysis, Renalytix stock appears to be undervalued. The current stock price of $4.11 is trading 62% below its estimated GF Value™ of $10.82.

Key valuation signals for RNLXD:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $10.82 vs. price of $4.11 (62% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the RNLXD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renalytix Business Description

Other Exchanges RENXF:USARENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
46GF Score

Get the complete analysis for RNLXD

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.11
Price
$10.82
GF Value